Compare Stocks

→ Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$18.09 +4.6%	$15.60	$9.50 ▼ $18.85	$1.64B	1.6	1.23 million shs	985,675 shs
LCI Lannett		$1.54	$0.64 ▼ $3.72	$7.38M	0.95	92,067 shs	280,600 shs
OBSV ObsEva	$0.01	$0.02	$0.08 ▼ $2.14	$390K	0.68	8.94 million shs	7,009 shs
OPTN OptiNose	$0.97 -6.0%	$1.49	$0.86 ▼ $2.10	$109.01M	-0.24	545,924 shs	671,563 shs
PVOTF BetterLife Pharma		$0.13	$0.03 ▼ $0.38	$21.70M	N/A	52,703 shs	198,200 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	-0.17%	+8.19%	+0.46%	+22.09%	+63.98%
LCI Lannett	0.00%	0.00%	0.00%	0.00%	0.00%
OBSV ObsEva	+150.00%	+1,150.00%	-60.00%	-85.71%	-93.98%
OPTN OptiNose	+15.19%	-13.45%	-36.81%	-27.46%	-44.92%
PVOTF BetterLife Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Pentagon contract could send this $2 AI stock soaring (Ad)

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

Get all the info here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	3.2184 of 5 stars	4.5	2.0	0.0	0.0	3.2	1.7	0.6
LCI Lannett	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OBSV ObsEva	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	3.151 of 5 stars	3.5	3.0	0.0	4.2	0.0	2.5	0.6
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$22.57	24.77% Upside
LCI Lannett	N/A	N/A	N/A	N/A
OBSV ObsEva	N/A	N/A	N/A	N/A
OPTN OptiNose	3.00	Buy	$4.00	313.35% Upside
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest OPTN, AVDL, PVOTF, OBSV, and LCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
3/18/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/18/2024	OPTN OptiNose	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $4.00
3/11/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$5.00
3/5/2024	AVDL Avadel Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
3/5/2024	AVDL Avadel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$18.00 ➝ $23.00
3/5/2024	AVDL Avadel Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$27.00 ➝ $29.00
3/5/2024	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $25.00
3/5/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
2/6/2024	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$27.96M	58.60	N/A	N/A	$0.98 per share	18.46
LCI Lannett	$340.58M	0.00	N/A	N/A	($23.34) per share	0.00
OBSV ObsEva	$20.11M	0.02	N/A	N/A	$0.41 per share	0.01
OPTN OptiNose	$70.99M	1.54	N/A	N/A	($0.77) per share	-1.26
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$160.28M	-$2.04	N/A	21.80	N/A	N/A	-198.06%	-84.51%	5/2/2024 (Estimated)
LCI Lannett	-$231.62M	-$18.88	N/A	N/A	N/A	-62.40%	N/A	-13.39%	N/A
OBSV ObsEva	-$58.38M	-$0.92	N/A	∞	N/A	N/A	-416.36%	-92.01%	N/A
OPTN OptiNose	-$35.48M	-$0.32	N/A	N/A	N/A	-50.06%	N/A	-33.05%	5/9/2024 (Estimated)
PVOTF BetterLife Pharma	-$14.78M	N/A	N/A	N/A	N/A	N/A	-205.15%	-147.23%	N/A

Latest OPTN, AVDL, PVOTF, OBSV, and LCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	12/31/2023	OPTN OptiNose	-$0.10	-$0.09	+$0.01	-$0.09	$19.90 million	$19.87 million
3/4/2024	Q4 2023	AVDL Avadel Pharmaceuticals	-$0.28	-$0.32	-$0.04	-$0.29	$17.41 million	$19.45 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LCI Lannett	N/A	N/A	N/A	N/A	N/A
OBSV ObsEva	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	3.64	3.36
LCI Lannett	N/A	2.23	1.39
OBSV ObsEva	N/A	0.61	0.61
OPTN OptiNose	N/A	0.60	0.55
PVOTF BetterLife Pharma	N/A	3.62	3.62

Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
LCI Lannett	40.28%
OBSV ObsEva	17.52%
OPTN OptiNose	85.60%
PVOTF BetterLife Pharma	N/A

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.00%
LCI Lannett	13.12%
OBSV ObsEva	14.40%
OPTN OptiNose	2.20%
PVOTF BetterLife Pharma	34.77%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	154	90.58 million	86.95 million	Optionable
LCI Lannett	810	10.77 million	9.35 million	Optionable
OBSV ObsEva	48	77.97 million	66.74 million	Not Optionable
OPTN OptiNose	132	112.65 million	110.17 million	Not Optionable
PVOTF BetterLife Pharma	N/A	171.41 million	N/A	Not Optionable

OPTN, AVDL, PVOTF, OBSV, and LCI Headlines

Source	Headline
	Jardiance and Ofev propel Boehringer’s human pharma sales msn.com - April 17 at 2:48 PM
	Vertex Pharma scientist talks about the long road to developing non-addictive painkillers abcnews.go.com - April 15 at 12:36 PM
	Pharmacy defends Eli Lilly off-label drug suit lifesciencesipreview.com - April 11 at 2:26 PM
	BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference tmcnet.com - April 11 at 9:26 AM
	Victory Over Big Pharma Will Take More Than the IRA msn.com - April 4 at 8:20 PM
	Liberals Need to Be Radicals prospect.org - April 4 at 10:19 AM
	Pharma is betting big on connecting potential patients to its medications. It's just the beginning endpts.com - April 3 at 2:37 AM
	AEVIS VICTORIA SA - Fabrice Zumbrunnen to become… pharmiweb.com - March 13 at 4:50 AM
	Presence of Particulates Prompts Recall of Treprostinil Injection empr.com - March 13 at 4:50 AM
	In Vietnam’s Mekong Delta, the lure of moving to the city grows even stronger amid climate shocks kdvr.com - March 12 at 10:24 PM
	America’s Last Top Models newyorker.com - March 12 at 10:24 PM
	Profile: Xi Jinping the reformer chinadaily.com.cn - March 12 at 12:23 PM
	BetterLife Pharma Inc.: BetterLife's 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University finanznachrichten.de - March 4 at 1:49 PM
	India continues fast economic growth but FDI falls sharply global.chinadaily.com.cn - March 1 at 8:26 AM
	GenesisCare Completes Reorganisation and Emerges from Chapter 11 pharmiweb.com - February 19 at 3:51 PM
	Immigrant Execs Give Back to OC ocbj.com - February 5 at 9:25 PM
	The tragedy of Leonard Farruku, the gifted young musician whose dream of a better life ended on the Bibby Stockholm theguardian.com - February 5 at 9:25 PM
	Weight loss drugs could create the first $1 trillion pharma companies msn.com - February 1 at 9:57 AM
	Roff: Medicare prescription price controls will hurt seniors news-journal.com - January 31 at 11:57 PM
	Budget 2024 Live Updates: Infrastructure, income tax, fiscal deficit, job creation announcements expected from FM Sitharaman's Union Budget timesofindia.indiatimes.com - January 31 at 11:57 PM
	BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001 finance.yahoo.com - January 2 at 10:19 AM
	Big Pharma scrambles to feed demand for weight-loss treatments amid rising U.S. obesity rates nbcnewyork.com - November 16 at 5:01 PM
	Big Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity rates msn.com - November 16 at 12:01 PM
	US Patent and Trademark Office Publishes BetterLife's Comprehensive Patent for BETR-001 and Other LSD Derivatives tmcnet.com - November 15 at 12:13 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Avadel Pharmaceuticals

NASDAQ:AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Lannett

NYSE:LCI

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.

ObsEva

NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

OptiNose

NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

BetterLife Pharma

OTCMKTS:PVOTF

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial